Cargando…

Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment

Background: Neuropsychiatric symptoms (NPS) are associated with faster decline in mild cognitive impairment (MCI). This study aimed to investigate the association between NPS severity and Alzheimer’s disease (AD) biomarkers, i.e., amyloid-β (Aβ), phosphorylated tau protein (p-tau) and hippocampal vo...

Descripción completa

Detalles Bibliográficos
Autores principales: Arenare, Giulia, Manca, Riccardo, Caffarra, Paolo, Venneri, Annalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452057/
https://www.ncbi.nlm.nih.gov/pubmed/37626552
http://dx.doi.org/10.3390/brainsci13081195
_version_ 1785095572499202048
author Arenare, Giulia
Manca, Riccardo
Caffarra, Paolo
Venneri, Annalena
author_facet Arenare, Giulia
Manca, Riccardo
Caffarra, Paolo
Venneri, Annalena
author_sort Arenare, Giulia
collection PubMed
description Background: Neuropsychiatric symptoms (NPS) are associated with faster decline in mild cognitive impairment (MCI). This study aimed to investigate the association between NPS severity and Alzheimer’s disease (AD) biomarkers, i.e., amyloid-β (Aβ), phosphorylated tau protein (p-tau) and hippocampal volume ratio (HR), to characterise in more detail MCI patients with a poor prognosis. Methods: A total of 506 individuals with MCI and 99 cognitively unimpaired older adults were selected from the ADNI dataset. The patients were divided into three different groups based on their NPI-Q total scores: no NPS (n = 198), mild NPS (n = 160) and severe NPS (n = 148). Regression models were used to assess the association between the severity of NPS and each biomarker level and positivity status. Results: Cerebrospinal fluid Aβ levels were positively associated with older age and lower MMSE scores, while higher p-tau levels were associated with female sex and lower MMSE scores. Only patients with severe NPS had a lower HR (β = −0.18, p = 0.050), i.e., more pronounced medio-temporal atrophy, than those without NPS. Discussion: Only HR was associated with the presence of NPS, partially in line with previous evidence showing that severe NPS may be explained primarily by greater grey matter loss. Future longitudinal studies will be needed to ascertain the relevance of this finding.
format Online
Article
Text
id pubmed-10452057
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104520572023-08-26 Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment Arenare, Giulia Manca, Riccardo Caffarra, Paolo Venneri, Annalena Brain Sci Article Background: Neuropsychiatric symptoms (NPS) are associated with faster decline in mild cognitive impairment (MCI). This study aimed to investigate the association between NPS severity and Alzheimer’s disease (AD) biomarkers, i.e., amyloid-β (Aβ), phosphorylated tau protein (p-tau) and hippocampal volume ratio (HR), to characterise in more detail MCI patients with a poor prognosis. Methods: A total of 506 individuals with MCI and 99 cognitively unimpaired older adults were selected from the ADNI dataset. The patients were divided into three different groups based on their NPI-Q total scores: no NPS (n = 198), mild NPS (n = 160) and severe NPS (n = 148). Regression models were used to assess the association between the severity of NPS and each biomarker level and positivity status. Results: Cerebrospinal fluid Aβ levels were positively associated with older age and lower MMSE scores, while higher p-tau levels were associated with female sex and lower MMSE scores. Only patients with severe NPS had a lower HR (β = −0.18, p = 0.050), i.e., more pronounced medio-temporal atrophy, than those without NPS. Discussion: Only HR was associated with the presence of NPS, partially in line with previous evidence showing that severe NPS may be explained primarily by greater grey matter loss. Future longitudinal studies will be needed to ascertain the relevance of this finding. MDPI 2023-08-12 /pmc/articles/PMC10452057/ /pubmed/37626552 http://dx.doi.org/10.3390/brainsci13081195 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arenare, Giulia
Manca, Riccardo
Caffarra, Paolo
Venneri, Annalena
Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
title Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
title_full Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
title_fullStr Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
title_full_unstemmed Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
title_short Associations between Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers in People with Mild Cognitive Impairment
title_sort associations between neuropsychiatric symptoms and alzheimer’s disease biomarkers in people with mild cognitive impairment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452057/
https://www.ncbi.nlm.nih.gov/pubmed/37626552
http://dx.doi.org/10.3390/brainsci13081195
work_keys_str_mv AT arenaregiulia associationsbetweenneuropsychiatricsymptomsandalzheimersdiseasebiomarkersinpeoplewithmildcognitiveimpairment
AT mancariccardo associationsbetweenneuropsychiatricsymptomsandalzheimersdiseasebiomarkersinpeoplewithmildcognitiveimpairment
AT caffarrapaolo associationsbetweenneuropsychiatricsymptomsandalzheimersdiseasebiomarkersinpeoplewithmildcognitiveimpairment
AT venneriannalena associationsbetweenneuropsychiatricsymptomsandalzheimersdiseasebiomarkersinpeoplewithmildcognitiveimpairment
AT associationsbetweenneuropsychiatricsymptomsandalzheimersdiseasebiomarkersinpeoplewithmildcognitiveimpairment